Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer
- 1Department of Oncology, General Hospital of Northern Theater Command
Abstract
Background: Gemcitabine (GEM) resistance limits treatment efficacy in bladder cancer (BC). This study identified MAN1B1 as a key driving factor for chemotherapy resistance and malignant progression in BC.
Methods: Bulk-RNA datasets GSE190636 and single-cell RNA-seq dataset GSE250523 from GEO. Use limma package to identify differentially expressed genes (DEGs) in the process of GEM resistance, and then perform GO and KEGG enrichment analysis. Screening candidate targets through molecular docking with GEM, and further evaluation through molecular dynamics simulation and GEPIA survival analysis. GSEA analysis is used to explore pathways associated with key genes. Perform single-cell analysis using Seurat, SingleR, Monocle 2, CellChat, and scTenifoldKnk, including cell annotation, pseudo time trajectory, intercellular communication, and virtual knockout. Carry out functional experiments in bladder cancer cell lines, including cell viability, wound healing Transwell, Colony formation and Western blot analysis.
Results: Through comprehensive transcriptome analysis and single-cell sequencing, we found that elevated levels of MAN1B1 are associated with poorer clinical outcomes. Computational molecular docking and molecular dynamics simulations indicate the potential binding interaction between MAN1B1 and GEM.This enzyme orchestrates a dual microenvironmental reprogramming by hyperactivating metabolic cascades while simultaneously dampening anti-tumor immune surveillance, predominantly originating from the epithelial compartment to modulate intercellular crosstalk. Functional disturbance experiments showed that knockout of MAN1B1 was associated with decreased cell survival, migration, and invasion, as well as increased sensitivity to GEM, while ectopic expression of MAN1B1 increased cell survival and was associated with enhanced PI3K/AKT/mTOR pathway activity.
Conclusions: Our findings uncover the multifaceted regulatory network governing MAN1B1, establishing its utility as an innovative prognostic indicator and an actionable therapeutic vulnerability for overcoming GEM insensitivity in urological oncology.
Related
- Integrated Transcriptomic Analysis and Experimental Validation Identify ATF3 as a Mesangial Cell-Associated Candidate Regulator in IgA Nephropathy
- Integrative Multi-Omics Reveals TSPAN13 as a Candidate Epithelial–Mesenchymal Transition-Associated Regulator in Prostate Cancer
- Beyond Sulfation: Integrated Immunohistochemical, Genomic, and Proteomic Profiling Identifies PAPSS1 as a Potential Regulator of Breast Cancer Progression.
- Integrated Transcriptomic Analysis Identifies ENO3 as a Candidate Lactate Metabolism‐Associated Biomarker in Colorectal Cancer Metastasis
- Identification of candidate selenium-associated transcriptomic biomarkers in chronic obstructive pulmonary disease: an integrated bioinformatics and expression validation study
BibTeX
@article{jiang2026integrated,
title = {{Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer}},
author = {Mingzhe Jiang and Dong Zhao and Liang Zhang and Dantong Zhu and Jia Li and Zhendong Zheng},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1958628},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1958628/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrated analyses identify MAN1B1 as a candidate regulator of chemotherapeutic tolerance and immunosuppression in bladder cancer
AU - Mingzhe Jiang
AU - Dong Zhao
AU - Liang Zhang
AU - Dantong Zhu
AU - Jia Li
AU - Zhendong Zheng
PY - 2026
DA - 2026/10/07
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1958628
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1958628/full
AB - Background: Gemcitabine (GEM) resistance limits treatment efficacy in bladder cancer (BC). This study identified MAN1B1 as a key driving factor for chemotherapy resistance and malignant progression in BC. Methods: Bulk-RNA datasets GSE190636 and single-cell RNA-seq dataset GSE250523 from GEO. Use limma package to identify differentially expressed genes (DEGs) in the process of GEM resistance, and then perform GO and KEGG enrichment analysis. Screening candidate targets through molecular docking with GEM, and further evaluation through molecular dynamics simulation and GEPIA survival analysis. GSEA analysis is used to explore pathways associated with key genes. Perform single-cell analysis using Seurat, SingleR, Monocle 2, CellChat, and scTenifoldKnk, including cell annotation, pseudo time trajectory, intercellular communication, and virtual knockout. Carry out functional experiments in bladder cancer cell lines, including cell viability, wound healing Transwell, Colony formation and Western blot analysis. Results: Through comprehensive transcriptome analysis and single-cell sequencing, we found that elevated levels of MAN1B1 are associated with poorer clinical outcomes. Computational molecular docking and molecular dynamics simulations indicate the potential binding interaction between MAN1B1 and GEM.This enzyme orchestrates a dual microenvironmental reprogramming by hyperactivating metabolic cascades while simultaneously dampening anti-tumor immune surveillance, predominantly originating from the epithelial compartment to modulate intercellular crosstalk. Functional disturbance experiments showed that knockout of MAN1B1 was associated with decreased cell survival, migration, and invasion, as well as increased sensitivity to GEM, while ectopic expression of MAN1B1 increased cell survival and was associated with enhanced PI3K/AKT/mTOR pathway activity. Conclusions: Our findings uncover the multifaceted regulatory network governing MAN1B1, establishing its utility as an innovative prognostic indicator and an actionable therapeutic vulnerability for overcoming GEM insensitivity in urological oncology.
SN - 1664-3224
ER -